Evidence map›Paper›PMID 31836926›Full record

ReviewVirchows Archiv : an international journal of pathology2020

Thirty years of Epstein-Barr virus-associated gastric carcinoma.

Masashi Fukayama, Hiroyuki Abe, Akiko Kunita, Aya Shinozaki-Ushiku, Keisuke Matsusaka, Tetsuo Ushiku, Atsushi Kaneda

Abstract readReview
PubMed Publisher
In one paragraph

Review in Virchows Archiv : an international journal of pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. [Diffuse gastric carcinoma in the youth: Case report].Revista medica del Instituto Mexicano del Seguro Social · 2024
    Article
  10. Article
  11. Claudin 18.2 as a novel therapeutic target.Nature reviews. Clinical oncology · 2024
    Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. A standardized pathology report for gastric cancer: 2nd edition.Journal of pathology and translational medicine · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Masashi FukayamaDepartment of Pathology, Graduate School of Medicine, University of Tokyo, Hongo 7-3-1, Tokyo, 113-0033, Japan. mfukayama-tky@umin.org.ORCID http://orcid.org/0000-0002-0460-064X
Hiroyuki AbeDepartment of Pathology, Graduate School of Medicine, University of Tokyo, Hongo 7-3-1, Tokyo, 113-0033, Japan.
Akiko KunitaDepartment of Pathology, Graduate School of Medicine, University of Tokyo, Hongo 7-3-1, Tokyo, 113-0033, Japan.
Aya Shinozaki-UshikuDepartment of Pathology, Graduate School of Medicine, University of Tokyo, Hongo 7-3-1, Tokyo, 113-0033, Japan.
Keisuke MatsusakaDepartment of Pathology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Tetsuo UshikuDepartment of Pathology, Graduate School of Medicine, University of Tokyo, Hongo 7-3-1, Tokyo, 113-0033, Japan.
Atsushi KanedaDepartment of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
The University of Tokyo · JPChiba University · JPAsahi General Hospital · JP

Funding

Grants-in-Aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Science 16K19074Grants-in-Aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Science 26253021Grants-in-Aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Science 26860232the Core Research for Evolutionary Science and Technology program from the Japan Science and Technology Agency 16gm0510010h0005the Core Research for Evolutionary Sciene and Technology Program from Japan Science and Technology Agency 16m0510010h005
6 · The paper itself

Abstract

Thirty years have passed since a possible association of Epstein-Barr virus (EBV) with gastric carcinoma was reported. We now know EBV-associated gastric carcinoma to be a specific subtype of gastric carcinoma. Global epigenetic methylation and counteraction of the antitumour microenvironment are two major characteristics of this subtype of gastric carcinoma. Recent development of therapeutic modalities for gastric carcinoma, such as endoscopic mucosal dissection and immune checkpoint inhibitor therapy, has made the presence of EBV infection a biomarker for the treatment of gastric carcinoma. This review presents a portrait of EBV-associated gastric carcinoma from initiation to maturity that we define as the 'gastritis-infection-cancer sequence', followed by its molecular abnormalities and interactions with immune checkpoint molecules and the microenvironment. EBV non-coding RNAs (microRNA and circular RNA) and exosomes derived from EBV-infected cells that were previously behind the scenes are now recognized for their roles in EBV-associated gastric carcinoma. The virus utilizes cellular machinery skilfully to control infected cells and their microenvironment. We should thus strive to understand virus-host interactions more fully in the following years to overcome this virus-driven subtype of gastric carcinoma.

Indexed as

Cell Transformation, ViralEpstein-Barr Virus InfectionsHumansStomach NeoplasmsDNA methylationEpstein-Barr virusExosomeGastric carcinomaGastritisImmune evasionInfectionMicroRNA

Identifiers

PMID31836926
OpenAlexW2995948556

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.